Eight For 8: Things You Need To Know About China Biopharma Regulation In 2018
The Pink Sheet's pick of eight major events that captured major regulatory developments in China’s dynamic, highly fluid biopharma scene in 2018.
You may also be interested in...
Biopharma investor sentiment plunged at the end 2018, but soared as the J.P. Morgan Healthcare Conference kicked off with another big company acquisition and as industry participants indicated their optimism about financing and deal-making opportunities in 2019.
Amid a global uproar denouncing a Chinese scientist’s work to deliver gene-edited twin babies, worries emerge that other valuable future research in the area could be put on hold, effectively crippling industry experts and researchers.
In a busy week for new drug approvals in China, the NMPA hands out nods for anticancers Elunate and Lenvima, rare disease treatment Soliris, and an additional indication for Humira, with Elunate being hailed by developer Chi-Med as the first fully "Made in China" novel oncology drug to receive unconditional approval.